22UA Stock Overview A biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for BioNTech Historical stock prices Current Share Price US$99.60 52 Week High US$110.60 52 Week Low US$77.15 Beta 0.17 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change -55.99% 5 Year Change n/a Change since IPO -61.54%
Recent News & Updates
BioNTech SE And its Partner OncoC4 Inc. Continue Enrollment In Phase 3 Trial For BNT316/ONC-392 After FDA Lifts Partial Hold Dec 14
Duality Biologics and BioNTech Present Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors At the ESMO Asia Congress 2024 Dec 06 BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million. Nov 15
BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million. Nov 13
Third quarter 2024 earnings released: EPS: €0.82 (vs €0.67 in 3Q 2023) Nov 05
BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024 Oct 21 See more updates
BioNTech SE And its Partner OncoC4 Inc. Continue Enrollment In Phase 3 Trial For BNT316/ONC-392 After FDA Lifts Partial Hold Dec 14
Duality Biologics and BioNTech Present Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors At the ESMO Asia Congress 2024 Dec 06 BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million. Nov 15
BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million. Nov 13
Third quarter 2024 earnings released: EPS: €0.82 (vs €0.67 in 3Q 2023) Nov 05
BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024 Oct 21
BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510) Oct 18 Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union Sep 20
New major risk - Revenue and earnings growth Sep 16 Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine Aug 23
Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age Aug 16
University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH Aug 07
BioNTech SE Reiterates Earnings Guidance for the Year 2024 Aug 06
BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024 Jul 22
BioNTech SE Reiterates Revenue Guidance for the Full Year 2024 May 08
BioNTech SE to Report Q1, 2024 Results on May 06, 2024 Apr 23
BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024 Mar 20
BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer Mar 08
BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305 Feb 01
BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer Jan 23
Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE Jan 17
BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer Dec 22 BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.
BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024 Nov 07
Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19 Oct 28
BioNTech SE, Annual General Meeting, May 17, 2024 Oct 21
BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication Oct 20
Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany Oct 01
Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine Sep 29 Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine Sep 12
BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023 Aug 15
BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023 Aug 08 BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million. Aug 01
BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023 Jul 25
BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC Jun 30
BioNTech SE Provides Revenue Guidance for the Full Year 2023 May 10 BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163 Dec 22 Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years Dec 06
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages Nov 19
Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection Nov 18
Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union Nov 12
BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022 Nov 08
Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine Nov 05
Pfizer and Biontech Receive Positive CHMP Opinion for Comirnaty® in Children 6 Months to Less Than 5 Years in the European Union Oct 20
Pfizer and BioNTech Announce Positive Early Data from Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older Oct 14
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age Oct 13
Pfizer Canada ULC and BioNTech SE's Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older Oct 08
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age Sep 27
Pfizer Inc. and BioNTech SE Receive Positive Chmp Opinion for Conversion of Comirnaty® Conditional Marketing Authorization to Full Marketing Authorization in the European Union Sep 18
Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster in European Union Sep 13
Biontech Presents Encouraging Phase 1/2 Follow-Up Data for Car-T Candidate Bnt211 in Hard-To-Treat Solid Tumors At ESMO Sep 10
Pfizer Inc. and BioNTech SE Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union Sep 02
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older Sep 01 Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months Through 4 Years of Age Aug 24 Pfizer and Biontech Submits Application to U.S. FDA for Emergency Use Authorization of Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Aug 23
BioNTech Reiterates Revenue Guidance for the Full Year 2022 Aug 09
Second quarter 2022 earnings released: EPS: €6.88 (vs €11.42 in 2Q 2021) Aug 08
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy with Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design Jul 28
Pfizer Inc. and BioNTech SE Submits Variation to the European Medicines Agency Jul 12
Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine Comirnaty for Adolescents 12 Through 15 Years of Age Jul 09
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech Jul 06
Investor sentiment improved over the past week Jun 28
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron Jun 27
BioNTech SE Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer Jun 24
Pfizer and BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age Jun 18
BioNTech SE Announces Positive Phase 1 Data from MRNA-Based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer Presented At ASCO Jun 06 BioNTech SE Approves Board Appointments
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose May 24
BioNTech SE and Pfizer Inc. Announces the U.S. Food and Drug Administration Expands Emergency Use Authorization May 19 Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission Shareholder Returns 22UA BG Biotechs BG Market 7D 0% 0% 0% 1Y n/a 0% 0%
See full shareholder returns
Return vs Industry: Insufficient data to determine how 22UA performed against the BG Biotechs industry .
Return vs Market: Insufficient data to determine how 22UA performed against the BG Market .
Price Volatility Is 22UA's price volatile compared to industry and market? 22UA volatility 22UA Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in BG Market 0% 10% least volatile stocks in BG Market 0%
Stable Share Price: 22UA's share price has been volatile over the past 3 months compared to the BG market.
Volatility Over Time: Insufficient data to determine 22UA's volatility change over the past year.
About the Company BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors.
Show more BioNTech SE Fundamentals Summary How do BioNTech's earnings and revenue compare to its market cap? 22UA fundamental statistics Market cap €25.98b Earnings (TTM ) -€466.90m Revenue (TTM ) €3.04b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 22UA income statement (TTM ) Revenue €3.04b Cost of Revenue €476.90m Gross Profit €2.56b Other Expenses €3.03b Earnings -€466.90m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 10, 2025
Earnings per share (EPS) -1.95 Gross Margin 84.31% Net Profit Margin -15.36% Debt/Equity Ratio 0%
How did 22UA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 06:10 End of Day Share Price 2024/11/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BioNTech SE is covered by 29 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Zhiqiang Shu Berenberg Etzer Darout BMO Capital Markets Equity Research
Show 26 more analysts 